DeepVerge (DVRG) announced an organisational restructure of its environmental and life science divisions. Modern Water will focus primarily on markets in China, South Asia and EMEA. Labskin and Skin Trust
DeepVerge (DVRG) announced an organisational restructure of its environmental and life science divisions. Modern Water will focus primarily on markets in China, South Asia and EMEA. Labskin and Skin Trust
Harland & Wolff Group (HARL), the infrastructure projects group, released further details following yesterday’s announcement by the Secretary of State, The Rt Hon Ben Wallace MP, at the Appledore Shipyard
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Alkemy,
DeepVerge (AIM: DVRG), announced that Gerard Brandon, Executive Director with responsibility for the Modern Water Division, has resigned and will leave the Company with immediate effect to enable him to
AfriTin Mining (ATM), an African technology metals mining company, announced results for the lithium and tantalum infill drilling programme at the company’s flagship operation, the Uis Mine.
Another busy week across the mining resources sector, here is our weekly recap.
East Star Resources (EST), the Kazakhstan-focused explorer, announced the results of analysis of rock chips collected across the company’s five volcanogenic massive sulphide Rudny Altai belt licences from geological reconnaissance
As l have been saying the last couple of weeks, with so many basement bargain stocks around, and with resources, demand is outgrowing supplies, something has to give, sooner rather
AfriTin Mining Limited (AIM: ATM), an African technology-metals mining company with a portfolio of mining and exploration assets in Namibia, announces a project update on the expansion of the processing
United Kingdom Government Releases the ‘UK’s Critical Minerals Strategy’ Policy, Paper
Poolbeg Pharma (POLB), a clinical-stage infectious disease pharmaceutical company, said it has received ethics and competent authority approval to commence its Lipopolysaccharide human challenge clinical trial for POLB 001, which